Creating vaccines for Respiratory Syncytial Virus (RSV) using computer models
Development and testing of RSV vaccines using a computational framework of virus-host interaction
This study is looking at new ways to create vaccines for Respiratory Syncytial Virus (RSV) to help protect children and older adults from getting seriously ill, using computer models to find the best combinations of viral proteins that can boost the immune response.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11004958 on NIH RePORTER |
What this research studies
This research focuses on developing vaccines for Respiratory Syncytial Virus (RSV), a leading cause of hospitalization in children and the elderly. By using computer simulations, the study aims to evaluate different vaccine formulations that combine various viral proteins to enhance the immune response. The researchers will analyze how these polyvalent vaccines can induce stronger antibody responses against conserved regions of the virus. This innovative approach seeks to improve vaccine effectiveness and potentially reduce RSV-related hospitalizations.
Who could benefit from this research
Good fit: Ideal candidates for this research include children under 11 years old and elderly individuals who are at higher risk for RSV-related complications.
Not a fit: Patients who are not at risk for RSV or those who have already been vaccinated against RSV may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective RSV vaccines, reducing hospitalizations and improving health outcomes for vulnerable populations.
How similar studies have performed: Previous research has shown promise in using polyvalent vaccine formulations to enhance immune responses, indicating that this approach could be effective.
Where this research is happening
Rochester, United States
- University of Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Anderson, Christopher S — University of Rochester
- Study coordinator: Anderson, Christopher S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.